Holen Sie sich die Stockscreener-App
2.9565
4.63%
-0.1435
Schlusskurs vom Vortag:
$3.10
Offen:
$3.178
24-Stunden-Volumen:
1,629
Relative Volume:
0.20
Marktkapitalisierung:
$4.63M
Einnahmen:
$2.54M
Nettoeinkommen (Verlust:
$-4.13M
KGV:
-1.0751
EPS:
-2.75
Netto-Cashflow:
$-4.11M
1W Leistung:
-1.45%
1M Leistung:
-4.63%
6M Leistung:
-33.71%
1J Leistung:
-25.72%
1-Tages-Spanne:
$2.9075
$3.178
1-Wochen-Bereich:
$2.9075
$3.2999
52-Wochen-Spanne:
$2.20
$5.20
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Firmenname
Xenetic Biosciences Inc
Sektor
Branche
Telefon
781-778-7720
Adresse
945 CONCORD ST., FRAMINGHAM, MA
Vergleichen Sie XBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
2.9565 | 4.63M | 2.54M | -4.13M | -4.11M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-01-08 | Eingeleitet | Maxim Group | Buy |
Xenetic Biosciences Inc Aktie (XBIO) Neueste Nachrichten
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update - Defense World
Head-To-Head Survey: Xenetic Biosciences (NASDAQ:XBIO) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Equities Analysts Set Expectations for XBIO Q2 Earnings - Defense World
Xenetic Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Xenetic (XBIO) Reports Strong Revenue Growth for Q1 | XBIO Stock News - GuruFocus
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial R - GuruFocus
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - ACCESS Newswire
Xenetic Reports 16% Revenue Growth, Expands Cancer Drug Development with New Clinical Partnerships - Stock Titan
Xenetic Biosciences: Q1 Earnings Snapshot - The Washington Post
Renaissance Technologies LLC Acquires 9,700 Shares of Xenetic Biosciences Inc (NASDAQ:XBIO) - Defense World
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma - Barchart.com
Xenetic Biosciences Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView
Xenetic Biosciences, Inc. Announces Executive Leadership Transition - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Xenetic Biosciences (XBIO) to Release Earnings on Thursday - Defense World
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - ACCESS Newswire
Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update - ACCESS Newswire
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - ACCESS Newswire
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses - ACCESS Newswire
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - ACCESS Newswire
Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results - ACCESS Newswire
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference - ACCESS Newswire
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - ACCESS Newswire
Xenetic Biosciences, Inc. Appoints Accomplished Biopharmaceutical Executive, Greg MacMichael, Ph.D. to Scientific Advisory Board - ACCESS Newswire
Xenetic Biosciences, Inc. to Present at BIO Investor Forum - ACCESS Newswire
Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM) - ACCESS Newswire
Finanzdaten der Xenetic Biosciences Inc-Aktie (XBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):